Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics Inc (RLMD)
:RLMD
Total Valuation
Relmada Therapeutics has a market cap or net worth of $294.07M. The enterprise value is $52.83M.
Market Cap$294.07M
Enterprise Value$52.83M
Share Statistics
Relmada Therapeutics has 73,333,626 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding73,333,626
Owned by Insiders4.05%
Owned by Institutions4.88%
Financial Efficiency
Relmada Therapeutics’s return on equity (ROE) is -2.25 and return on invested capital (ROIC) is -236.14%.
Return on Equity (ROE)-2.25
Return on Assets (ROA)-1.75
Return on Invested Capital (ROIC)-236.14%
Return on Capital Employed (ROCE)-2.36
Revenue Per Employee0.00
Profits Per Employee-4.70M
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Relmada Therapeutics is ―. Relmada Therapeutics’s PEG ratio is 0.01.
PE Ratio―
PS Ratio0.00
PB Ratio0.44
Price to Fair Value0.44
Price to FCF-0.30
Price to Operating Cash Flow-2.83
PEG Ratio0.01
Income Statement
In the last 12 months, Relmada Therapeutics had revenue of 0.00 and earned -79.98M in profits. Earnings per share was -2.65.
Revenue0.00
Gross Profit0.00
Operating Income-83.89M
Pretax Income-79.98M
Net Income-79.98M
EBITDA-83.89M
Earnings Per Share (EPS)-2.65
Cash Flow
In the last 12 months, operating cash flow was -39.99M and capital expenditures 0.00, giving a free cash flow of -39.99M billion.
Operating Cash Flow-39.99M
Free Cash Flow-39.99M
Free Cash Flow per Share-0.55
Dividends & Yields
Relmada Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.98
52-Week Price Change1085.71%
50-Day Moving Average3.26
200-Day Moving Average1.36
Relative Strength Index (RSI)51.93
Average Volume (3m)1.13M
Important Dates
Relmada Therapeutics upcoming earnings date is Mar 24, 2026, After Close (Confirmed).
Last Earnings DateNov 13, 2025
Next Earnings DateMar 24, 2026
Ex-Dividend Date―
Financial Position
Relmada Therapeutics as a current ratio of 4.45, with Debt / Equity ratio of 0.00%
Current Ratio4.45
Quick Ratio4.45
Debt to Market Cap0.00
Net Debt to EBITDA0.05
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Relmada Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Relmada Therapeutics EV to EBITDA ratio is -0.15, with an EV/FCF ratio of -0.23.
EV to Sales0.00
EV to EBITDA-0.15
EV to Free Cash Flow-0.23
EV to Operating Cash Flow-0.23
Balance Sheet
Relmada Therapeutics has $13.89M in cash and marketable securities with $0.00 in debt, giving a net cash position of $13.89M billion.
Cash & Marketable Securities$13.89M
Total Debt$0.00
Net Cash$13.89M
Net Cash Per Share$0.19
Tangible Book Value Per Share$1.18
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Relmada Therapeutics is $10.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$10.00
Price Target Upside342.48% Upside
Analyst ConsensusModerate Buy
Analyst Count1
Revenue Growth Forecast―
EPS Growth Forecast37.37%